Upexi, Inc.

As of September 28, 2022, Upexi, Inc. is considered risky due to its extreme P/B ratio of 229.66, negative EV to EBITDA of -44.95, and a concerning ROE of -616.52%, indicating overvaluation and financial challenges compared to peers, despite a strong year-to-date return of 94.3%.

As of October 15, 2023, Upexi, Inc. is considered undervalued with a P/E ratio of 12.5 and a P/B ratio of 1.8, indicating an attractive investment compared to peers like Greenlane Holdings and KushCo Holdings.

As of October 1, 2023, there is insufficient technical data for Upexi, Inc. to determine if it is bullish or bearish.

Upexi, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $3 million and a net loss of $4 million as of March 2025. Key metrics include a market cap of $363.61 million, a debt-to-equity ratio of 3.90, and a return on equity of -616.52%.

As of Jun 18, Upexi, Inc. has a market capitalization of 363.61 million, with net sales of 16.75 million and a net profit of -11.15 million over the latest four quarters. As of Jun 24, the company reported shareholder's funds of 6.52 million and total assets of 23.51 million.